jeudi 30 novembre 2017

Onco Actu du 30 novembre 2017

1. Biologie

Six-Letter DNA Alphabet Produces Proteins in Cells [The Scientist]

‘Alien’ DNA makes proteins in living cells for the first time [Nature]

3.1 Prévention - Tabac

Advancing Medicinal Nicotine Replacement Therapies as New Drugs – A new step in FDA’s comprehensive approach to tobacco and nicotine [FDA Voice]

Quitting smoking is hard. FDA wants new nicotine-replacement therapies to help [Washington Post]

4.1 Dép., diag. & prono. - Prostate

Less Frequent Biopsies May Be Appropriate for PCa Active Surveillance [Renal & Urology News]

4.2 Dép., diag. & prono. - Génome

Genomics – on an industrial scale [Genomics England]

4.9 Dép., diag. & prono. - Sein

Overweight Women May Need More Frequent Mammograms [Oncology Times]

5. Traitements

Tito Fojo: Cancer drugs not delivering on their potential [Cancer World]

5.1 Traitements - Pré-clinique

Inhibiting METTL3 destroys AML cells without harming normal blood cells [Drug Target Review]

New Technique Reduces Side-Effects, Improves Delivery of Chemotherapy Nanodrugs [Carnegie Mellon]

5.10 Traitements - Essais

EFPIA-PhRMA Principles successfully enable responsible clinical trial data sharing [PhRMA]

5.12.2 Immunothérapies - CAR-T

bluebird bio Acquires Manufacturing Facility in North Carolina and Executes Multiple Global Supply Agreements to Enhance Ability to Deliver Gene Therapies to Patients [bluebird bio]

A Virus Shortage? BlueBird Bio Buys A Factory To Make Its Own [Forbes]

Bluebird bio orchestrates a series of deals and a buyout to guarantee gene therapy manufacturing [EndPoints]

The Most Promising Cancer Treatments in a Century Have Arrived – But Not For Everyone [Wired]

5.12.5 Immunothérapies - Pharma

Merck drafts game plan for lung cancer with awareness campaign expansion [FiercePharma]

5.12.8 Immunothérapies - Economie

Pharma's Paradox: Cure A Deadly Childhood Disease And Then Get Attacked On Price [Forbes]

5.2.3 Pharma - économie

New backers Sofinnova and Scopia bring Y-mAb’s round to $80M for anti-cancer drugs [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

New EU Guidelines on Good Manufacturing Practices for Advanced Therapies [ESMO]

New EMA CHMP Guideline on the Evaluation of Anticancer Medicinal Products in Man [ESMO]

5.8.2 ASH - Pharma

Bristol-Myers Squibb to Present New Data Across a Broad Range of Blood Cancers at the 59th Annual Meeting & Exposition of the American Society of Hematology [BMS]

6.10.1 Politiques (USA)

Alex Azar, Trump’s HHS nominee, says addressing drug prices would be his top priority [STAT]

If Joe Biden runs for president, he’ll need to reboot his record on drug prices [STAT]

Health secretary nominee Azar says lowering drug prices a top priority [Reuters]

6.3 Associations/Fondations

U.S. says patient charity helped drugmakers, revokes approval [Reuters]